Research ArticleOriginal Article
Open Access

Single nucleotide polymorphisms in cytokine genes and their association with primary Sjögren’s syndrome in Saudi patients

A cross-sectional study

Bashaer Alqahtani, Maha Daghestani, Mohammed A. Omair, Fahidah Alenzi, Esam H. Alhamad, Yusra Tashkandy, Nashwa Othman, Arjumand Warsy and Rabih Halwani
Saudi Medical Journal December 2023, 44 (12) 1232-1239; DOI: https://doi.org/10.15537/smj.2023.44.12.20230490

References

  1. 1.↵
    1. Gøransson LG,
    2. Haldorsen K,
    3. Brun JG,
    4. Harboe E,
    5. Jonsson MV,
    6. Skarstein K, et al.
    The point prevalence of clinically relevant primary Sjögren’s syndrome in 2 Norwegian counties. Scand J Rheumatol 2011; 40: 221–224.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Pers JO,
    2. Lahiri A,
    3. Tobón GJ,
    4. Youinou, P
    . Pathophysiological cytokine network in primary Sjögren’s syndrome. Presse Med 2012; 41: e467–e474.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Björk A,
    2. Mofors J,
    3. Wahren‐Herlenius, M
    . Environmental factors in the pathogenesis of primary Sjögren’s syndrome. J Intern Med 2020; 287: 475–492.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Fletes-Rayas AL,
    2. Palafox-Sánchez CA,
    3. Muñoz-Valle JF,
    4. Orozco-Barocio G,
    5. Navarro-Hernández RE,
    6. Oregon-Romero, E
    .TNFR1-383 A>C polymorphism association with clinical manifestations in primary Sjögren’s syndrome patients. Genet Mol Res 2016; 15.
  5. 5.
    1. Liu M,
    2. Wu X,
    3. Liu X,
    4. He J,
    5. Su Y,
    6. Guo J,
    7. Li Z
    . Contribution of dendritic cell immunoreceptor (DCIR) polymorphisms in susceptibility of systemic lupus erythematosus and primary Sjogren’s syndrome. Hum Immunol 2015; 76: 808–811.
    OpenUrl
  6. 6.↵
    1. Magnusson V,
    2. Nakken B,
    3. Bolstad AI,
    4. Alarcón-Riquelme, ME
    . Cytokine polymorphisms in systemic lupus erythematosus and Sjogren’s syndrome. Scand J Immunol 2001; 54: 55–61.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Lessard CJ,
    2. Li H,
    3. Adrianto I,
    4. Ice JA,
    5. Rasmussen A,
    6. Grundahl KM, et al.
    Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjogren’s syndrome. Nat Genet 2013; 45: 1284–1292.
    OpenUrlCrossRefPubMed
  8. 8.
    1. Fogel O,
    2. Rivière E,
    3. Seror R,
    4. Nocturne G,
    5. Boudaoud S,
    6. Ly B, et al.
    Role of the IL-12/IL-35 balance in patients with Sjögren syndrome. J Allergy Clin Immunol 2018; 142: 258–268.
    OpenUrlPubMed
  9. 9.↵
    1. Imgenberg-Kreuz J,
    2. Rasmussen A,
    3. Sivils K,
    4. Nordmark G
    . Genetics and epigenetics in primary Sjögren’s syndrome. Rheumatology (Oxford) 2021; 60: 2085–2098.
    OpenUrlCrossRef
  10. 10.↵
    1. AlEnzi F,
    2. Alqahtani B,
    3. Alhamad EH,
    4. Daghestani M,
    5. Tashkandy Y,
    6. Othman N, et al.
    Fatigue in Saudi patients with primary Sjögren’s syndrome and its correlation with disease characteristics and outcome measures: A cross-sectional study. Open Access Rheumatol 2020; 12: 303–308.
    OpenUrl
  11. 11.↵
    1. Omair MA,
    2. AlQahtani BS,
    3. AlHamad EH,
    4. Tashkandy YA,
    5. Othman NS,
    6. AlShahrani KA, et al.
    Disease phenotype and diagnostic delay in Saudi patients with primary Sjögren’s syndrome. Saudi Med J 2021; 42: 405–410.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Shiboski CH,
    2. Shiboski SC,
    3. Seror R,
    4. Criswell LA,
    5. Labetoulle M,
    6. Lietman TM, et al.
    2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: A consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis 2017; 76: 9–16.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Seror R,
    2. Theander E,
    3. Brun JG,
    4. Ramos-Casals M,
    5. Valim V,
    6. Dörner T, et al.
    Validation of EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis 2015; 74: 859–866.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    Case control studies: Tests for deviation from Hardy-Weinberg equilibrium and tests for association. (n.d.). Institut für Humangenetik. [Accessed 2020 April 15]. Available from: https://ihg.gsf.de/cgi-bin/hw/hwa1.pl---
  15. 15.↵
    1. Nezos A,
    2. Mavragani CP
    . Contribution of genetic factors to Sjögren’s syndrome and Sjögren’s syndrome related lymphomagenesis. J Immunol Res 2015; 2015: 754825.
    OpenUrl
  16. 16.
    1. Papageorgiou A,
    2. Mavragani CP,
    3. Nezos A,
    4. Zintzaras E,
    5. Quartuccio L,
    6. De Vita S, et al.
    A BAFF receptor His159Tyr mutation in Sjögren’s syndrome–related lymphoproliferation. Arthritis Rheumatol 2015; 67: 2732–2741.
    OpenUrl
  17. 17.↵
    1. Reksten TR,
    2. Lessard CJ,
    3. Sivils KL
    . Genetics in Sjögren syndrome. Rheum Dis Clin North Am 2016; 42: 435–447.
    OpenUrl
  18. 18.↵
    1000 Genomes Project Consortium. A global reference for human genetic variation. Nature 2015; 526: 68.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Takahashi JL,
    2. Giuliani F,
    3. Power C,
    4. Imai Y,
    5. Yong VW
    . Interleukin‐1β promotes oligodendrocyte death through glutamate excitetoxicity. Ann Neurol 2003; 53; 588–595.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    1. Pociot F,
    2. Mølvig J,
    3. Wogensen L,
    4. Worsaae H,
    5. Nerup J
    . A Taql polymorphism in the human interleukin‐1β (IL‐1β) gene correlates with IL‐1β secretion in vitro. Eur J Clin Investig 1992; 22: 396–402.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    1. El-Omar EM,
    2. Carrington M,
    3. Chow WH,
    4. McColl KE,
    5. Bream JH,
    6. Young HA, et al.
    Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404: 398–402.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    1. Ponomarenko MP,
    2. Suslov VV,
    3. Gunbin KV,
    4. Ponomarenko PM,
    5. Vishnevsky OV,
    6. Kolchanov NA
    . Identification of the relationship between the variability of the expression of signaling pathway genes in the human brain and the affinity of TATA-binding protein to their promoters. Russ J Genet Appl Res 2015; 5: 626–634.
    OpenUrl
  23. 23.↵
    1. Muraki Y,
    2. Tsutsumi A,
    3. Takahashi R,
    4. Suzuki E,
    5. Hayashi T,
    6. Chino Y, et al.
    Polymorphisms of IL-1 beta gene in Japanese patients with Sjögren’s syndrome and systemic lupus erythematosus. J Rheumatol 2004; 31: 720–725.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Priya EK,
    2. Srinivas L,
    3. Rajesh S,
    4. Sasikala K,
    5. Banerjee M
    . Pro-inflammatory cytokine response pre-dominates immuno-genetic pathway in development of rheumatoid arthritis. Mol Biol Rep 2020; 47: 8669–8677.
    OpenUrl
  25. 25.
    1. Younes HEM,
    2. Ghonaim MM,
    3. Elkhyat AH,
    4. Labeeb AA,
    5. El-Hefnawy SM,
    6. Dawoud AM
    . Polymorphisms of interleukin-1β and cytotoxic T lymphocyte associated antigen-4 genes in systemic lupus erythematosus. Egypt J Med Microbiol 2019; 28.
  26. 26.
    1. Yin Y,
    2. Liu Y,
    3. Pan X,
    4. Chen R,
    5. Li P,
    6. Wu HJ, et al.
    Interleukin-1β promoter polymorphism enhances the risk of sleep disturbance in Alzheimer’s disease. PLoS One 2016; 11: e0149945.
    OpenUrl
  27. 27.↵
    1. Yadav DK,
    2. Tripathi AK,
    3. Gupta D,
    4. Shukla S,
    5. Singh AK,
    6. Kumar A, et al.
    Interleukin-1B (IL-1B-31 and IL-1B-511) and interleukin-1 receptor antagonist (IL-1Ra) gene polymorphisms in primary immune thrombocytopenia. Blood Res 2017; 52: 264–269.
    OpenUrl
  28. 28.↵
    1. Mattuzzi S,
    2. Barbi S,
    3. Carletto A,
    4. Ravagnani V,
    5. Moore PS,
    6. Bambara LM, et al.
    (2007). Association of polymorphisms in the IL1B and IL2 genes with susceptibility and severity of systemic sclerosis. J Rheumatol 2007; 34: 997–1004.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Mohammadoo-Khorasani M,
    2. Salimi S,
    3. Tabatabai E,
    4. Sandoughi M,
    5. Zakeri Z,
    6. Farajian-Mashhadi F
    . Interleukin-1β (IL-1β) & IL-4 gene polymorphisms in patients with systemic lupus erythematosus (SLE) & their association with susceptibility to SLE. Indian J Med Res 2016; 143: 591.
    OpenUrl
  30. 30.↵
    1. Fu LY,
    2. Qiu X,
    3. Deng QL,
    4. Huang P,
    5. Pi L,
    6. Xu Y, et al.
    The IL-1B gene polymorphisms rs16944 and rs1143627 contribute to an increased risk of coronary artery lesions in Southern Chinese Children with Kawasaki disease. J Immunol Res 2019; 2019: 4730507.
    OpenUrl
  31. 31.↵
    1. Lee KA,
    2. Ki CS,
    3. Kim HJ,
    4. Sohn KM,
    5. Kim JW,
    6. Kang WK, et al.
    Novel interleukin 1β polymorphism increased the risk of gastric cancer in a Korean population. J Gastroenterol 2004; 39: 429–433.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    1. Wang L,
    2. Zhao W,
    3. Hong J,
    4. Niu F,
    5. Li J,
    6. Zhang S, et al.
    Association between IL1B gene and cervical cancer susceptibility in Chinese Uygur Population: A case-control study. Mol Genet Genomic Med 2019; 7: e779.
    OpenUrl
  33. 33.↵
    1. Tak KH,
    2. Yu GI,
    3. Lee MY,
    4. Shin DH
    . Association between polymorphisms of interleukin 1 family genes and hepatocellular carcinoma. Med Sci Monit 2018; 24: 3488.
    OpenUrl
  34. 34.↵
    1. Yencilek F,
    2. Yildirim A,
    3. Yilmaz SG,
    4. Altinkilic EM,
    5. Dalan AB,
    6. Bastug Y, et al.
    Investigation of interleukin-1β polymorphisms in prostate cancer. Anticancer Res 2015; 35: 6057–6061.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Liu X,
    2. Wang Z,
    3. Yu J,
    4. Lei G,
    5. Wang S, et al.
    Three polymorphisms in interleukin-1β gene and risk for breast cancer: a meta-analysis. Breast Cancer Res Treat 2010; 124: 821–825.
    OpenUrlCrossRefPubMedWeb of Science
  36. 36.↵
    1. Nordmark G,
    2. Kristjansdottir G,
    3. Theander E,
    4. Eriksson P,
    5. Brun JG,
    6. Wang C, et al.
    Additive effects of the major risk alleles of IRF5 and STAT4 in primary Sjögren’s syndrome. Genes Immun 2009; 10: 68–76.
    OpenUrlCrossRefPubMedWeb of Science
  37. 37.↵
    1. Imgenberg-Kreuz J,
    2. Sandling JK,
    3. Almlöf JC,
    4. Nordlund J,
    5. Signér L,
    6. Norheim KB, et al.
    Genome-wide DNA methylation analysis in multiple tissues in primary Sjögren’s syndrome reveals regulatory effects at interferon-induced genes. Ann Rheum Dis 2016; 75: 2029–2036.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Sigurdsson S,
    2. Göring HH,
    3. Kristjansdottir G,
    4. Milani L,
    5. Nordmark G,
    6. Sandling JK, et al.
    (2008). Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus. Human Molecular Genetics 2008; 17: 872–881.
    OpenUrlCrossRefPubMedWeb of Science
  39. 39.
    1. Ferreiro-Neira I,
    2. Calaza M,
    3. Alonso-Perez E,
    4. Marchini M,
    5. Scorza R,
    6. Sebastiani GD, et al.
    (2007). Opposed independent effects and epistasis in the complex association of IRF 5 to SLE. Genes & Immunity 2007; 8:429–438.
    OpenUrl
  40. 40.
    1. Taylor KE,
    2. Chung SA,
    3. Graham RR,
    4. Ortmann WA,
    5. Lee AT,
    6. Langefeld CD, et al.
    Risk alleles for systemic lupus erythematosus in a large case-control collection and associations with clinical subphenotypes. PLoS Genetics 2011; 7: e1001311.
    OpenUrl
  41. 41.
    1. Alarcón‐Riquelme ME,
    2. Ziegler JT,
    3. Molineros J,
    4. Howard TD,
    5. Moreno‐Estrada A,
    6. Sánchez‐Rodríguez E, et al.
    Genome‐wide association study in an Amerindian ancestry population reveals novel systemic lupus erythematosus risk loci and the role of European admixture. Arthritis Rheumatol 2016; 68: 932–943.
    OpenUrl
  42. 42.
    1. Zervou MI,
    2. Dorschner JM,
    3. Ghodke-Puranik Y,
    4. Boumpas DT,
    5. Niewold TB,
    6. Goulielmos GN
    . Association of IRF5 polymorphisms with increased risk for systemic lupus erythematosus in population of Crete, a southern-eastern European Greek island. Gene 2017; 610: 9–14.
    OpenUrlCrossRefPubMed
  43. 43.
    1. Carmona FD,
    2. Onat AM,
    3. Fernández-Aranguren T,
    4. Serrano-Fernández A,
    5. Robledo G,
    6. Direskeneli H, et al.
    J Analysis of systemic sclerosis-associated genes in a Turkish population. J Rheumatol 2016; 43: 1376–1379.
    OpenUrlAbstract/FREE Full Text
  44. 44.
    1. Graham RR,
    2. Hom G,
    3. Ortmann W,
    4. Behrens TW
    . Review of recent genome‐wide association scans in lupus. J Intern Med 2009; 265: 680–688.
    OpenUrlCrossRefPubMedWeb of Science
  45. 45.
    1. Elghzaly AA,
    2. Metwally SS,
    3. El-Chennawi FA,
    4. Elgayaar MA,
    5. Mosaad YM,
    6. El-Toraby EE, et al.
    IRF5, PTPN22, CD28, IL2RA, KIF5A, BLK and TNFAIP3 genes polymorphisms and lupus susceptibility in a cohort from the Egypt Delta; relation to other ethnic groups. Hum Immunol 2015; 76: 525–531.
    OpenUrlCrossRefPubMed
  46. 46.↵
    1. Stock CJ,
    2. De Lauretis A,
    3. Visca D,
    4. Daccord C,
    5. Kokosi M,
    6. Kouranos V, et al.
    Defining genetic risk factors for scleroderma-associated interstitial lung disease. Clin Rheumatol 2020; 39: 1173–1179.
    OpenUrl
  47. 47.↵
    1. Batten M,
    2. Groom J,
    3. Cachero TG,
    4. Qian F,
    5. Schneider P,
    6. Tschopp J, et al.
    BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 2000: 192: 1453–1466.
    OpenUrlAbstract/FREE Full Text
  48. 48.↵
    1. Nezos A,
    2. Papageorgiou A,
    3. Fragoulis G,
    4. Ioakeimidis D,
    5. Koutsilieris M,
    6. Tzioufas AG
    . B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren’s syndrome. J Autoimmun 2014; 51: 89–98.
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Theodorou E,
    2. Nezos A,
    3. Antypa E,
    4. Ioakeimidis D,
    5. Koutsilieris M,
    6. Tektonidou M, et al.
    B-cell activating factor and related genetic variants in lupus related atherosclerosis. J Autoimmun 2018; 92: 87–92.
    OpenUrl
  50. 50.↵
    1. Novak AJ,
    2. Slager SL,
    3. Fredericksen ZS,
    4. Wang AH,
    5. Manske MM,
    6. Ziesmer S, et al.
    Genetic variation in B-cell–activating factor is associated with an increased risk of developing B-cell non–Hodgkin lymphoma. Cancer Res 2009; 69: 4217–4224.
    OpenUrlAbstract/FREE Full Text
  51. 51.↵
    1. Han Q,
    2. Yang C,
    3. Li N,
    4. Li F,
    5. Sang J,
    6. Lv Y, et al.
    Association of genetic variation in B-cell activating factor with chronic hepatitis B virus infection. Immunol Lett 2017; 188: 53–58.
    OpenUrlCrossRef
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords